Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2016-12-08 AGM Information
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech: Rights issue approved by the extraordinary general meeting
AGM Information Classification · 98% confidence The document is explicitly titled 'PROTOKOLL FRA EKSTRAORDINÆR GENERALFORSAMLING' (Minutes from Extraordinary General Meeting) in both Norwegian and English. It details the proceedings, resolutions passed (like electing a chairman and approving a guaranteed rights issue), and the attendance records of an Extraordinary General Meeting (EGM) held on December 8, 2016. This content directly corresponds to the documentation generated following a shareholder meeting, which falls under the scope of AGM Information (AGM-R), even though it is an EGM, as it captures the official record of the meeting's outcomes.
2016-12-08 Norwegian
PCI Biotech: Rights issue approved by the extraordinary general meeting
AGM Information Classification · 99% confidence The document explicitly discusses the approval of a 'Rights issue' by an 'extraordinary general meeting (EGM)'. While the EGM itself relates to shareholder voting (DVA), the core subject matter is the financing activity—the rights issue. A rights issue is a method of raising capital by offering new shares to existing shareholders. This directly aligns with the definition of 'Capital/Financing Update' (CAP). Although the minutes of the EGM are attached, the primary purpose of this announcement is to communicate the outcome and details of the capital raising event, not just the voting results or the general meeting presentation itself. Given the focus on the rights issue and associated dates (prospectus publication, payment date), CAP is the most appropriate classification over AGM-R or DVA.
2016-12-08 English
PCI Biotech: Disclosure of voting rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "PCI Biotech: Disclosure of voting rights" and details the number of shares held directly and the number of shares represented via powers of attorney by the Chairman (Hans Peter Bøhn) and the CEO (Per Walday) for an upcoming extraordinary general meeting on December 8, 2016. This directly relates to the voting structure and rights associated with the company's shares, specifically concerning a general meeting. This fits the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), as it discloses the voting power held by key insiders for an upcoming vote, even though the final results are not yet declared. It is not a general Director's Dealing (DIRS) as it focuses on voting power for a meeting, not general trading, and it is not an AGM-R as it is a disclosure notice, not the meeting material itself.
2016-12-07 English
Financial calendar
Report Publication Announcement Classification · 99% confidence The document is titled 'Financial calendar' and lists scheduled dates for future corporate events, specifically 'Quarterly Report', 'Annual Report', and 'Annual General Meeting' for the years 2016 and 2017. It is not the report itself, nor is it an announcement of a specific report release that has already occurred. It is a forward-looking schedule of corporate events. This type of general scheduling information does not fit neatly into the specific categories like ER, IR, 10-K, or AGM-R (which is for materials *from* the AGM). Since it is a general corporate announcement regarding future reporting schedules, the most appropriate fallback category is Regulatory Filings (RNS), as it is a required disclosure about the company's schedule.
2016-11-23 English
PCI Biotech: Third quarter 2016 results
Interim / Quarterly Report Classification · 100% confidence The document is a 'Third Quarter Report 2016' for PCI Biotech. It contains detailed financial figures (income statement, cash flow), operational reviews of the company's programs (fimaCHEM, fimaVACC, fimaNAC), and management commentary. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q3 2016
2016-11-22 English
PCI Biotech: Third quarter 2016 results
Earnings Release Classification · 100% confidence The document explicitly states it contains the "financial report for third quarter 2016 for PCI Biotech Holding ASA." It provides key highlights, financial updates (including a proposed rights issue), and a CEO comment. This structure strongly indicates a comprehensive report covering a period shorter than a year (Q3). Therefore, it fits the definition of an Interim / Quarterly Report (IR). Although it mentions the report is 'enclosed,' the content provided is substantial enough to be the report summary itself, not just a brief announcement of publication (which would lean towards RPA/RNS). The mention of 'Third quarter 2016 results' confirms the periodic nature. Q3 2016
2016-11-22 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.